Clinical trials: Untreated, active
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma.
- Conditions
- Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Trial name
- NCT04404088
- Testing
- Acalabrutinib, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received…
- Trial name
- NCT06136559
- Testing
- Nemtabrutinib, Ibrutinib, Acalabrutinib
- Where
- 206 sites in United States, Australia and 27 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Nasopharyngeal Carcinoma (NPC)
A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma
Proton therapy for nasopharyngeal carcinoma can reduce radiotherapy-related toxic reactions, and some retrospective studies have found that proton therapy improves the survival of patients with nasopharyngeal carcinoma.
- Trial name
- NCT07578727
- Testing
- Proton Therapy System (ProBeam), Photon Therapy System (TrueBeam)
- Where
- 2 sites in China
- Volunteers
- 504 people
- Sponsor
- Guangzhou Concord Cancer Center
X-Linked Retinitis Pigmentosa
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants…
- Trial name
- NCT04850118
- Testing
- rAAV2tYF-GRK1-hRPGRco, Control
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 85 people
- Sponsor
- Beacon Therapeutics
Urothelial Cancer
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer.
- Trial name
- EV-302 (NCT04223856)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- 260 sites in United States, Argentina and 23 more
- Volunteers
- 886 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma
MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Single-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma (EMZL). It is planned to recruit 130 patients.
- Conditions
- Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
- Trial name
- MALIBU (NCT03697512)
- Testing
- Ibrutinib, Rituximab
- Where
- 36 sites in Belgium, France and 3 more
- Volunteers
- 175 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Head and Neck Cancer, HPV
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and…
- Trial name
- NCT07065630
- Testing
- Volrustomig, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Chicago
Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas.
- Conditions
- Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
- Trial name
- NCT07535762
- Testing
- Aclarubicin, Cyclophosphamide, Vincristine
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Mantle Cell Lymphoma
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
This phase II trial studies how well ibrutinib works in treating participants with untreated high risk smoldering mental cell lymphoma.
- Trial name
- NCT03282396
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia.
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- Trial name
- NCT02115295
- Testing
- Cladribine, Cytarabine, Gilteritinib
- Where
- United States
- Volunteers
- 508 people
- Sponsor
- M.D. Anderson Cancer Center
First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication
The goal of this project is to investigate whether a systematic screening approach enhanced by an innovative model of communicating information about psychosis and treatment options to patients and families (ComPsych) can reduce…
- Trial name
- EaSIE (NCT05509998)
- Testing
- Screening Method (SM), Screening and Communication Method (SCM)
- Where
- United States
- Volunteers
- 912 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has…
- Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- NCT07392892
- Testing
- PF-08634404, Chemotherapy, Nivolumab
- Where
- 102 sites in United States, Canada and 8 more
- Volunteers
- 840 people
- Sponsor
- Pfizer
Extensive Stage Lung Small Cell Carcinoma
LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of LB-100 when given together with carboplatin, etoposide, and atezolizumab for the treatment of untreated extensive-stage small cell lung cancer.
- Trial name
- NCT04560972
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Previously Untreated Peripheral T-Cell Lymphoma
A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
The goal of this clinical study is to find the best way to combine the study drug BEBT-908 (ifupinostat hydrochloride for injection) with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for treating previously…
- Trial name
- NCT07676175
- Testing
- Ifupinostat Hydrochloride for Injection, Cyclophosphamide for Injection, Doxorubicin Hydrochloride for Injection
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- BeBetter Med Inc
Non-Tuberculous Mycobacterial Pneumonia
Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fibrosis
This study evaluates a diagnostic serological test for Non-Tuberculous Mycobacteria (NTM) infection in cystic fibrosis patients by measuring T cell response.
- Trial name
- MUCEM (NCT06602869)
- Testing
- Scheduled visit (V1)
- Where
- France
- Volunteers
- 76 people
- Sponsor
- University Hospital, Montpellier
MCL, Mantle Cell Lymphoma
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL).
- Trial name
- ALTAMIRA (NCT05214183)
- Testing
- Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
- Where
- 20 sites in Denmark, Finland and 3 more
- Volunteers
- 81 people
- Sponsor
- Nordic Lymphoma Group
Untreated Myelodysplastic Syndrome
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
This phase I/II open-label, dose-finding, multi-center study will assess safety and primary efficacy of Onureg and Venetoclax combination, to define the optimal biological dose and optimal treatment duration of Onureg to be used…
- Trial name
- NCT05782127
- Testing
- Onureg + Venetoclax
- Where
- 25 sites in France
- Volunteers
- 36 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Leukemia, Myelodysplastic Syndromes
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
RATIONALE: Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and HT before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00544466
- Testing
- fludarabine phosphate, melphalan, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- City of Hope Medical Center
Chronic Hepatitis B
Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients
The World Health Organization (WHO) has set a target to eliminate viral hepatitis by 2030, aiming for a 90% diagnosis rate and an 80% treatment rate for chronic hepatitis B (CHB).
- Trial name
- Union-FAST (NCT07520123)
- Testing
- Agent Intelligence education
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma.
- Trial name
- OLYMPIA-2 (NCT06097364)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 145 sites in United States, Australia and 15 more
- Volunteers
- 733 people
- Sponsor
- Regeneron Pharmaceuticals